Pramlintide vs Retatrutide
Synthetic amylin analog for comprehensive postprandial glucose control with insulin therapy
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Pramlintide
30–60 mcg
Retatrutide
4–8 mg
Frequency
Pramlintide
Once daily
Retatrutide
Once weekly
Administration
Pramlintide
subcutaneous injection
Retatrutide
Subcutaneous injection
Cycle length
Pramlintide
Ongoing/indefinite
Retatrutide
12+ weeks
Onset speed
Pramlintide
Moderate (1-2 weeks)
Retatrutide
Moderate (1-2 weeks)
Evidence level
Pramlintide
Strong human trials (Phase 3 or FDA approved)
Retatrutide
Moderate human trials (Phase 1-2)
Benefit ratings
Blood Sugar Control
Weight Management
Metabolic Health
Weight Loss Power
Appetite Control
Compound specifications
Pramlintide
Molecular formula
C171H267N51O53S2
Molecular weight
3,949 Da
Half-life
~48 minutes
Bioavailability
30-40% subcutaneous bioavailability
CAS number
196078-30-5
Retatrutide
Molecular formula
C221H342N46O68
Molecular weight
4731 g/mol
Half-life
~6 days (allows once-weekly dosing)
Bioavailability
High via subcutaneous injection
CAS number
2381089-83-2
Dosing compared
Pramlintide
Subcutaneous
Titrate up after 3+ days without significant nausea
15 mcg per meal (type 1 diabetes)
Immediately before each major meal · Titrate up after 3+ days without significant nausea
FDA Symlin label starting dose for type 1 diabetes. Inject before each major meal (>=250 kcal or >=30 g carbohydrate); reduce mealtime insulin by 50% when starting. [6]
Ongoing, as tolerated
30-60 mcg per meal (type 1 diabetes)
Immediately before each major meal · Ongoing, as tolerated
Type 1 maintenance target per FDA label: titrate 15 -> 30 -> 45 -> 60 mcg, stepping up each time no significant nausea occurs for 3+ days; settle at 30 or 60 mcg as tolerated. [6]
Increase to 120 mcg after 3+ days without significant nausea
60 mcg per meal, titrating to 120 mcg (type 2 diabetes)
Immediately before each major meal · Increase to 120 mcg after 3+ days without significant nausea
FDA Symlin label for type 2 diabetes: start 60 mcg, advance to 120 mcg maintenance as tolerated. Separate injection from insulin; cut mealtime insulin 50% at start. [6]
Retatrutide
Subcutaneous
Weeks 1-4
2 mg
Once weekly · Weeks 1-4 (then escalate 2 mg every 4 weeks)
Phase 2 obesity trial initiated higher-dose arms at 2 mg weekly with stepwise 2 mg increases every 4 weeks to limit GI effects [1].
Maintenance after titration
4-8 mg
Once weekly · Maintenance after titration
Mid-range maintenance doses; 8 mg produced ~22% mean weight loss at 48 weeks in the phase 2 trial [1][3].
Maintenance (highest studied)
12 mg
Once weekly · Maintenance (highest studied)
Highest studied dose; produced ~24% mean weight reduction at 48 weeks [1]. Still investigational (not FDA-approved).
Best suited for
Pramlintide
Improving postprandial glucose control in insulin-treated diabetes
Pramlintide is particularly well-suited for individuals focused on improving postprandial glucose control in insulin-treated diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing insulin dose requirements while maintaining glycemic control
Pramlintide is particularly well-suited for individuals focused on reducing insulin dose requirements while maintaining glycemic control. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting weight management in insulin-treated T1DM and T2DM patients
Pramlintide is particularly well-suited for individuals focused on supporting weight management in insulin-treated t1dm and t2dm patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Addressing amylin deficiency in insulin-dependent diabetes
Pramlintide is particularly well-suited for individuals focused on addressing amylin deficiency in insulin-dependent diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Retatrutide
Significant Obesity Management
If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
Type 2 Diabetes with Obesity
Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
Metabolic Syndrome Warriors
If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
Fatty Liver Disease (MASLD)
Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.
Side effects
Pramlintide
Common
- Nausea
- Reduced Appetite / Anorexia
- Headache
Uncommon
- Abdominal Pain and Vomiting
- Injection Site Reactions
Serious
- Severe Hypoglycemia (BLACK BOX WARNING)
Retatrutide
Common
- Nausea
- Diarrhea
- Constipation
- Decreased appetite
Uncommon
- Increased heart rate
- Injection site reactions
Serious
- Pancreatitis
- Gallbladder problems
Safety & evidence
Pramlintide
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
FDA-approved pramlintide demonstrates good tolerability in insulin-treated diabetes with well-characterized safety profile from >20 years clinical use. Gastrointestinal side effects (nausea) occur in 30-50% of initiators but typically resolve within 1-3 weeks. Hypoglycemia risk, especially when combined with insulin, requires dose coordination and patient education. Pancreatic side effects theoretically possible but not documented in clinical trials. Pregnancy category C requires careful consideration.
Contraindications
- Confirmed gastroparesis requiring treatment
- Hypoglycemia unawareness (inability to recognize hypoglycemic symptoms)
- Known hypersensitivity to pramlintide or metacresol
- Pediatric patients (safety not established in children)
Retatrutide
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or planning to become pregnant
- History of severe pancreatitis
- Known allergy to GLP-1 receptor agonists
Which is right for you?
Choose Pramlintide if...
- Improving postprandial glucose control in insulin-treated diabetes
- Reducing insulin dose requirements while maintaining glycemic control
- Supporting weight management in insulin-treated T1DM and T2DM patients
- Addressing amylin deficiency in insulin-dependent diabetes
Choose Retatrutide if...
- Significant weight loss
- Type 2 diabetes management
- Metabolic health improvement
- Body composition optimization